Thaksin ends silence with philosophical tweet

Thaksin ends silence with philosophical tweet

Former prime minister Thaksin Shinawatra broke his long silence on Wednesday, with a single sentence on his @ThaksinLive Twitter account.

Former prime minister Thaksin Shinawatra's message on Twitter.

"Montesquieu once said 'There is no crueler tyranny than that which is perpetuated under the shield of law and in the name of the justice'," he wrote.

He was referring to a famous French philosopher. His message was sent without elaboration.

It was his first tweet since August 2015.

He wrote on his Facebook account in March this year that he would stop making comments, to avoid being seen as trying to disrupt the work of the junta.

Wednesday's message was posted after his young sister, former prime minister Yingluck, went into hiding. She failed to appear at the Supreme Court's Criminal Division for Holders of Political Positions on Friday to hear the ruling in her rice-pledging scheme trial.

Ms Yingluck is believed to have fled the country.

She is accused of dereliction of duty in failing to properly administer the scheme, leading to corruption and huge financial loss to the state. If convicted she faced up to 10 years in prison. A bench arrest warrant was issued and the court rescheduled delivery of its judgement to Sept 27.

Do you like the content of this article?

DR Congo reports fresh Ebola outbreak

KINSHASA - DR Congo reported a fresh Ebola outbreak in its northwest on Monday, the latest health emergency for a country already fighting an epidemic of the deadly fever in the east as well as a surging number of coronavirus infections.


Japan skies lit up to brighten mood

Simultaneous fireworks displays coloured the night skies in Tokyo and other parts of Japan on Monday, with fireworks makers hoping the sight would cheer up the nation as it struggles with the coronavirus pandemic.


Gilead: Remdesivir helped moderate patients improve

Gilead Sciences Inc said on Monday its antiviral drug remdesivir showed improvement in patients with moderate Covid-19 in a late-stage study.